Skip to main content
    R

    RenovoRx Inc (RNXT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.95
    -0.09 (-8.18%)

    Market Cap: $50.18M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    RenovoRx Inc (RNXT) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    RenovoRx (RNXT) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, RenovoRx reported EPS of -$0.07, below the -$0.05 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    45%(10/22)
    Avg Surprise
    +1.79%

    Upcoming Estimates

    Reports Mar 29, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.06
    Range-$0.07 - -$0.03
    6 analysts
    Revenue Consensus
    $1.37M
    Range$1.14M - $1.58M
    6 analysts
    Reports May 12, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.05
    Range-$0.06 - -$0.03
    2 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.07+35.7%
    60d ago-$0.05+10.0%
    30d ago-$0.05+10.0%
    7d ago-$0.05+10.0%
    Current-$0.05
    Revenue Consensus
    $1.54M
    Range$1.40M - $1.71M
    3 analysts

    Next Report

    RNXT has an expected report date of Mar 29, 2027.

    RNXT Earnings Call

    The latest RNXT earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 22 quarters below that had an estimate, RNXT beat 10, missed 6 and matched 6. Revenue for the quarter ended Sep 30, 2026 was $1.07M, up 302.3% from $266000 a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.07-$0.05-$0.07 - -$0.03-40.00%MissN/A20 up, 0 downNov 5, 2026$1.07M
    Jun 30, 2026-$0.05-$0.08-$0.08 - -$0.07+37.50%BeatN/A20 up, 1 downAug 12, 2026$909000
    Mar 31, 2026-$0.08-$0.08-$0.09 - -$0.070.00%In lineN/A32 up, 1 downMay 14, 2026$563000
    Dec 31, 2025-$0.08-$0.08-$0.08 - -$0.080.00%In lineN/A30 up, 1 downMar 30, 2026$238000
    Sep 30, 2025-$0.08-$0.08-$0.08 - -$0.080.00%In lineN/A20 up, 1 downNov 13, 2025$266000
    Jun 30, 2025-$0.08-$0.08-$0.08 - -$0.080.00%In lineN/A20 up, 1 downAug 14, 2025$422000
    Mar 31, 2025-$0.08-$0.08-$0.08 - -$0.070.00%In lineN/A22 up, 0 downMay 15, 2025$197000
    Dec 31, 2024-$0.12-$0.13-$0.13 - -$0.12+4.00%BeatN/A20 up, 1 downMar 31, 2025$43000
    Sep 30, 2024-$0.10-$0.12-$0.13 - -$0.11+16.67%BeatN/A30 up, 0 downNov 13, 2024N/A
    Jun 30, 2024-$0.10-$0.11-$0.11 - -$0.09+9.09%BeatN/A20 up, 0 downAug 13, 2024N/A
    Mar 31, 2024-$0.30-$0.30N/A0.00%In lineN/A21 up, 0 downApr 1, 2024N/A
    Dec 31, 2023-$0.31-$0.30-$0.31 - -$0.30-3.33%MissN/A30 up, 0 downMar 19, 2024N/A
    Sep 30, 2023-$0.13-$0.28N/A+53.57%BeatN/A10 up, 0 downNov 13, 2023N/A
    Jun 30, 2023-$0.22-$0.29N/A+24.14%BeatN/A10 up, 0 downAug 16, 2023N/A
    Mar 31, 2023-$0.36-$0.25-$0.25 - -$0.25-44.00%MissN/A10 up, 0 downMay 15, 2023N/A
    Dec 31, 2022-$0.23-$0.26-$0.26 - -$0.26+11.54%BeatN/A20 up, 0 downMar 2, 2023N/A
    Sep 30, 2022-$0.24-$0.29-$0.31 - -$0.27+17.24%BeatN/A20 up, 0 downNov 14, 2022N/A
    Jun 30, 2022-$0.29-$0.28N/A-3.57%MissN/AN/A0 up, 0 downAug 15, 2022N/A
    Mar 31, 2022-$0.33-$0.21-$0.25 - -$0.17-57.14%MissN/A20 up, 0 downMay 16, 2022N/A
    Dec 31, 2021-$0.12-$0.16-$0.18 - -$0.14+25.00%BeatN/A20 up, 0 downMar 30, 2022N/A
    Sep 30, 2021-$0.27-$0.21-$0.29 - -$0.13-28.57%MissN/A20 up, 0 downNov 15, 2021N/A
    Jun 30, 2021-$0.48-$0.58N/A+17.24%BeatN/AN/AN/AAug 27, 2021N/A
    Mar 31, 2021-$0.57N/AN/AN/AN/AN/AN/AN/AJun 30, 2021N/A
    Dec 31, 2020-$0.51N/AN/AN/AN/AN/AN/AN/AMar 30, 2021N/A
    Mar 31, 2020-$0.35N/AN/AN/AN/AN/AN/AN/AJun 29, 2020N/A
    Dec 31, 2019-$0.48N/AN/AN/AN/AN/AN/AN/AMar 31, 2020N/A
    Last 26 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.32, after -$0.62 the year before. It was -$0.48 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.32N/A
    Dec 31, 2024-$0.62N/A
    Dec 31, 2023-$1.02N/A
    Dec 31, 2022-$1.09N/A
    Dec 31, 2021-$1.44N/A
    Dec 31, 2020-$0.86N/A
    Dec 31, 2019-$0.48N/A

    Earnings Calls

    The 6 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,400 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20263,4318
    2026Q2Jun 30, 20264,3638
    2026Q1Mar 31, 20263,7938
    2025Q3Sep 30, 20253,5578
    2025Q2Jun 30, 20255,9918
    2025Q1Mar 31, 20252,3216

    2026Q3 Earnings Call

    Opening remarks

    Stephanie Carrington Managing Director, ICR Healthcare Thank you, operator. Good afternoon, and welcome, everyone, to the RenovoRx Third Quarter 2026 Earnings Results Conference Call. I am joined today by members of the leadership team, including Shaun Bagai, Chief Executive Officer; Dr. Ramtin Agah, Chief Medical Officer, Executive Chair and Founder; and Mark Voll, Chief Financial Officer. Before we begin, I'd like to remind everyone that statements made during today's call contain or may contain forward-looking statements covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and applicable federal securities laws. These statements, including statements regarding RenovoRx's commercial activities and strategies, clinical plans, and expectations of financial or operational performance, including projected revenues, projected active commercial cancer centers, and timing for completion and data readout of the company's TIGeR-PaC trial, are based on management's current plans and assumptions, and actual results may differ materially. Please refer to our filings with the SEC, including our Form 10-Q for the quarter ended September 30, 2026, for detailed discussion of the risks and uncertainties facing RenovoRx. With that, I'd like to turn over the call to our Chief Executive Officer, Shaun Bagai.

    Shaun Bagai CEO Thank you, Stephanie, and good afternoon, everyone. The third quarter of 2026 was a milestone quarter for RenovoRx as we continue to deliver on all three of our core priorities. First, for the first time in our history, quarterly revenue exceeded the $1 million threshold. Second, we grew our customer base of active commercial cancer centers, expanded our sales pipeline, and completed the build-out of our sales organization. Third, we advanced the expansion of our TAMP platform and RenovoCath device beyond locally advanced pancreatic cancer. In sum, we continue to deliver on multiple fronts. During the third quarter, RenovoRx generated record revenue of approximately $1.1 million, our strongest quarterly performance to date, increasing approximately 17% sequentially and nearly a 300% increase, or more than 4x higher year-over-year. Revenue for the first 9 months of 2026 was approximately $2.5 million, more than double our full-year 2025 revenue of $1.1 million. This is a direct, measurable result of the commercial model we have described. Every new commercial cancer center we activate drives more procedures and revenue, accelerating growth. Driving much of our growth is our fully staffed sales team, which continues to gain traction and accelerate customer engagement and adoption of TAMP. The sales team, comprised of a Vice President of Sales and Market Development and 5 regional market development managers, is strategically deployed to cover major U.S. cancer centers. Our focused and regionally deployed sales team is sufficiently sized to address the market and effectively penetrate cancer centers that treat solid tumors such as pancreatic cancer.

    Frequently Asked Questions About RNXT

    When is RenovoRx's next earnings date?

    RenovoRx's next earnings report is expected for Mar 29, 2027.

    Did RNXT beat earnings estimates last quarter?

    No. RenovoRx reported EPS of -$0.07 for the quarter ended Sep 30, 2026, below the -$0.05 estimate by 40.00%.

    What EPS do analysts expect from RNXT next quarter?

    The consensus EPS estimate for RenovoRx for the quarter ending Dec 31, 2026 is -$0.06 from 6 analysts, with estimates from -$0.07 to -$0.03.

    How often does RNXT beat earnings estimates?

    RenovoRx beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of +0.19%.